Share
Christoph Korpus
Byondis B.V., an independent biopharmaceutical company focused on developing innovative targeted therapies for cancer, has appointed Christoph Korpus, PhD, MBA, as its Chief Executive Officer (CEO).
Christoph previously served as the company’s Chief Business Officer (CBO) since January 2025.
He succeeds Byondis founder and former CEO Jacques Lemmens, PhD, who will continue to serve on the Board of Directors as Chairman.
In his role as CEO, Christoph Korpus will lead the continued advancement of Byondis’ research and development strategy, with a focus on its proprietary antibody-drug conjugate (ADC) technology platforms. These include cytotoxic antifolate linker-drug technologies, the ByonGuard™ masking technology enabling conditional activation, and the ByonBoost™ immune-stimulatory linker-drug platform. Together, these platforms have generated multiple lead and follow-on drug candidates across the company’s pipeline.
Byondis operates as a fully integrated biopharmaceutical organization, with in-house capabilities spanning discovery, development, and manufacturing, enabling independent progression of its lead programs. Alongside internal development, the company continues to explore strategic partnerships and licensing opportunities to support co-development and broader pipeline expansion.
Christoph Korpus brings over 15 years of experience in the biopharmaceutical sector, with expertise spanning oncology research and development, digital innovation, and global business development and licensing. Prior to joining Byondis, he was Director of Global Business Development and Licensing Oncology at Merck KGaA, where he led oncology partnering strategies and major transaction negotiations, while managing cross-functional global alliances across multiple therapeutic areas.
He holds a PhD from Ludwig-Maximilians-Universität Munich and the University of Connecticut, along with an MBA from the Kellogg School of Management at Northwestern University and WHU – Otto Beisheim School of Management.
